Enliven Therapeutics Inc - ELVN Net Assets per Single Share

Official company branding of Enliven Therapeutics, Inc. (ELVN)

The visualized price action of Enliven Therapeutics (ELVN) reflects market expectations for the commercialization of selective kinase inhibitors to combat leukemia, where the indicator stands at 12.16. Enliven Therapeutics is recognized as an innovator in developing drugs that overcome tumor resistance, garnering confidence from the scientific community. Current success relies on the R&D pipeline and early molecule testing under strict management of existing cash reserves.

ELVN Enliven Pharma Net Asset Value per Share (04/28/2023 - 10/29/2026)

ELVN (enliventherapeutics.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Quotes Enliven Pharma|ELVN - Price Target Chart
- issuer market value details:
Market Value Enliven Therapeutics, Inc.|ELVN - Business Value
- shareholders' equity book value data:
Net Assets per Single Share Enliven Therapeutics|ELVN - Total Stockholders' Equity|Market Value to Book Value Ratio enliventherapeutics.com|ELVN - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Enliven Therapeutics|ELVN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Enliven Therapeutics, Inc.|ELVN - Company Cumulative Debt|Debt to Book Capitalization Ratio Enliven Therapeutics, Inc.|ELVN - Company Long-Term Debt|Company Short-Term Debt Enliven Therapeutics
Basic company analysis:ELVN - Enliven Pharma
Manufactured products of Enliven Therapeutics, Inc.

The stability of the research and development cycle at Enliven Therapeutics (ELVN) is reflected in the dynamics of the net book value per share. This indicator captures the actual remaining capital available to shareholders after all liabilities have been settled. The calculation is performed by dividing the difference between assets and liabilities by the total number of shares. The high liquidity of the ELVN balance sheet minimizes the risk of frozen funds, confirming the company's fundamental resilience within the biotechnology sector.

Competitor analysis for Enliven Therapeutics

GMAB: Accounting Value per Share|EXEL: Net Assets per Single Share|Nuvalent, Inc. (NUVL) - Net Assets per Single Share|Equity per Share KYMR|Net Assets per Single Share IDEAYA Biosciences, Inc.|Net Asset Value per Share ORIC Pharmaceuticals Inc ORIC|Net Assets per Single Share Relay Pharma (RLAY)|Nurix Corp - Equity per Share|Book Value per Share TYRA (Tyra Biosciences, Inc.)|VSTM - Accounting Value per Share|GLUE - Net Assets per Single Share|Net Asset Value per Share Cullinan Oncology|Immuneering Inc. (IMRX) - Net Assets per Single Share|CCCC (C4 Therapeutics Corp) - Net Assets per Single Share|Net Assets per Single Share Black Diamond|Net Asset Value per Share reparerx.com RPTX|Book Value per Share PMVP|karyopharm.com (KPTI) - Book Value of One Share|Propanc Biopharma - Accounting Value per Share|Cyclacel (BGMS) - Net Asset Value per Share|AADI: Accounting Value per Share|Accounting Value of a Share ALRN (Aileron Therapeutics)|BPMC (blueprintmedicines.com) - Accounting Value per Share|GLYC: Book Price of a Share|SWTX (SpringWorks) - Book Value per Share